Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Cigna Group, consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Current insurance and contractholder liabilities	5,388)	5,514)	5,385)	5,318)	5,308)
Pharmacy and other service costs payable	28,465)	19,815)	17,070)	15,309)	13,347)
Accounts payable	9,294)	8,553)	7,775)	6,655)	5,478)
Accrued expenses and other liabilities	9,387)	9,955)	8,006)	7,322)	8,515)
Short-term debt	3,035)	2,775)	2,993)	2,545)	3,374)
Liabilities of businesses held for sale	2,410)	2,104)	—)	6,423)	—)
Current liabilities	57,979)	48,716)	41,229)	43,572)	36,022)
Non-current insurance and contractholder liabilities	10,254)	10,904)	11,481)	12,563)	16,844)
Deferred tax liabilities, net	6,975)	7,173)	7,751)	8,346)	8,939)
Other non-current liabilities	3,215)	3,441)	3,142)	3,762)	4,629)
Long-term debt	28,937)	28,155)	28,100)	31,125)	29,545)
Separate account liabilities	7,278)	7,430)	7,278)	8,337)	9,086)
Liabilities of businesses held for sale, non-current	—)	591)	—)	—)	—)
Non-current liabilities	56,659)	57,694)	57,752)	64,133)	69,043)
Total liabilities	114,638)	106,410)	98,981)	107,705)	105,065)
Redeemable noncontrolling interests	—)	107)	66)	54)	58)
Common stock, $0.01 par value per share	4)	4)	4)	4)	4)
Additional paid-in capital	31,288)	30,669)	30,233)	29,574)	28,975)
Accumulated other comprehensive loss	(2,341)	(1,864)	(1,395)	(884)	(861)
Retained earnings	43,519)	41,652)	37,874)	32,593)	28,575)
Treasury stock, at cost	(31,437)	(24,238)	(21,844)	(14,175)	(6,372)
Shareholders’ equity	41,033)	46,223)	44,872)	47,112)	50,321)
Other noncontrolling interests	210)	21)	13)	18)	7)
Total equity	41,243)	46,244)	44,885)	47,130)	50,328)
Total liabilities and equity	155,881)	152,761)	143,932)	154,889)	155,451)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Total liabilities and equity remained relatively stable in absolute terms, moving from 155.45 billion in 2020 to 155.88 billion in 2024. However, the internal composition of the balance sheet reveals a significant shift in the nature of obligations and the management of shareholder capital.

Current Liabilities and Operational Obligations: A marked increase is observed in current liabilities, which rose from 36.02 billion in 2020 to 57.98 billion in 2024. This trend is predominantly driven by pharmacy and other service costs payable, which more than doubled from 13.35 billion to 28.47 billion over the period. Accounts payable also showed a consistent upward trajectory, increasing from 5.48 billion in 2020 to 9.29 billion in 2024.
Non-Current Liabilities and Long-Term Debt: Non-current liabilities exhibited a downward trend, declining from 69.04 billion in 2020 to 56.66 billion in 2024. This reduction is largely attributable to the decrease in non-current insurance and contractholder liabilities, which fell from 16.84 billion to 10.25 billion. Long-term debt remained relatively stable, fluctuating within a range of 28.10 billion to 31.13 billion.
Equity and Capital Allocation: Total equity decreased from 50.33 billion in 2020 to 41.24 billion in 2024. A divergent pattern is noted within the equity components: retained earnings grew significantly from 28.58 billion to 43.52 billion, indicating strong profitability. However, this growth was offset by an aggressive share repurchase strategy, as treasury stock at cost increased from 6.37 billion in 2020 to 31.44 billion in 2024.
Other Comprehensive Income and Minority Interests: Accumulated other comprehensive losses expanded from 861 million in 2020 to 2.34 billion in 2024. Additionally, other noncontrolling interests saw a sharp increase in 2024, reaching 210 million compared to 21 million in 2023.

The analysis indicates a migration of the liability profile from long-term to short-term obligations, specifically within operational payables. While the company has generated substantial internal capital as evidenced by retained earnings, the overall reduction in shareholders' equity is a direct result of an intensified treasury stock program.

AI Ask an analyst for more

Download chart

Cigna Group (NYSE:CI)

Balance Sheet: Liabilities and Stockholders’ Equity